acetaminophen has been researched along with Adverse Drug Event in 191 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Of the 345 patients included in the study, elevated AST/ALT levels were attributed to rhabdomyolysis in 168 patients and attributed to acetaminophen toxicity in 177 patients." | 8.02 | Patterns of transaminase elevation in rhabdomyolysis versus acetaminophen toxicity. ( Maskell, KF; Okhomina, V; Powell, SW; Sima, AP; Willis, D; Wills, BK, 2021) |
| "The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure." | 7.96 | Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. ( Berlin, JA; Fife, D; Ryan, PB; Schuemie, MJ; Swerdel, J; Weinstein, RB, 2020) |
| "The purpose of this study was to investigate the risk of transitional cell carcinoma among subjects with an intake of acetaminophen, aspirin, some other drugs and with some intercurrent diseases." | 7.69 | Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. ( Gerhardsson de Verdier, M; Steineck, G; Wiholm, BE, 1995) |
| "Literature searches were performed using keywords: "paracetamol", "acetaminophen", "critical illness", "intensive care", "history", "pharmacology", "antipyre*", "analgesi*", "adverse effect*", "administration and dosage", "toxicity", "animals" and "humans"." | 4.88 | Paracetamol in critical illness: a review. ( Jefferies, S; Saxena, M; Young, P, 2012) |
| " In Europe and North America a large proportion of cases are due to acetaminophen and to idiosyncratic drug reactions, whereas reports from emerging countries in Asia and Africa feature viral illnesses, particularly hepatitis B and E." | 4.84 | Etiologies of acute liver failure. ( Lee, WM, 2008) |
| "Of the 345 patients included in the study, elevated AST/ALT levels were attributed to rhabdomyolysis in 168 patients and attributed to acetaminophen toxicity in 177 patients." | 4.02 | Patterns of transaminase elevation in rhabdomyolysis versus acetaminophen toxicity. ( Maskell, KF; Okhomina, V; Powell, SW; Sima, AP; Willis, D; Wills, BK, 2021) |
| "The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure." | 3.96 | Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. ( Berlin, JA; Fife, D; Ryan, PB; Schuemie, MJ; Swerdel, J; Weinstein, RB, 2020) |
| "We compared the incidence of adverse drug events of a two-bag IV acetylcysteine regimen with that of the traditional three-bag regimen." | 3.83 | Simplification of the standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. ( Graudins, A; Wong, A, 2016) |
| " I present the recent debate on the causal association between acetaminophen and asthma in order to illustrate the point at issue." | 3.79 | Until RCT proven? On the asymmetry of evidence requirements for risk assessment. ( Osimani, B, 2013) |
| "The purpose of this study was to investigate the risk of transitional cell carcinoma among subjects with an intake of acetaminophen, aspirin, some other drugs and with some intercurrent diseases." | 3.69 | Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. ( Gerhardsson de Verdier, M; Steineck, G; Wiholm, BE, 1995) |
| "Therapeutic experiments are commonly performed on laboratory animals to investigate the possible mechanism(s) of action of toxic agents as well as drugs or substances under consideration." | 2.82 | A review: Systematic research approach on toxicity model of liver and kidney in laboratory animals. ( Abbasnezhad, A; Mohebbati, R; Salami, F, 2022) |
| "Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF)." | 2.82 | Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review. ( Aithal, GP; Alvarez-Alvarez, I; Andrade, RJ; Arikan, C; Atallah, E; Lucena, MI; Medina-Caliz, I; Niu, H, 2022) |
| "Drug-induced liver injury (DILI) represents a serious medical challenge and a potentially fatal adverse event." | 2.53 | Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon? ( Antoine, DJ; Clarke, JI; Dear, JW, 2016) |
| "It is now widely appreciated that drug metabolites, in addition to the parent drugs themselves, can mediate the serious adverse effects exhibited by some new therapeutic agents, and as a result, there has been heightened interest in the field of drug metabolism from researchers in academia, the pharmaceutical industry, and regulatory agencies." | 2.47 | Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. ( Baillie, TA; Rettie, AE, 2011) |
| "Concern exists about the potential for liver injury with therapeutic dosing of acetaminophen in children." | 2.46 | Therapeutic acetaminophen is not associated with liver injury in children: a systematic review. ( Dart, RC; Lavonas, EJ; Reynolds, KM, 2010) |
| " Recent human clinical trials of drugs, including acetaminophen (APAP) and ximelagatran, have shown that the metabonomics of biofluids (plasma and urine) collected before and immediately after dosing can identify individual patients who are likely to develop DILI." | 2.46 | The application of metabonomics to predict drug-induced liver injury. ( O'Connell, TM; Watkins, PB, 2010) |
| "Malignancy is an uncommon cause of ALF, and thus imaging studies may not be useful in this setting, but liver biopsy may be beneficial in selected cases." | 2.44 | Epidemiology of acute liver failure. ( Khashab, M; Kwo, PY; Tector, AJ, 2007) |
| "Drug-induced acute liver failure (ALF) accounts for approximately 20% of ALF in children and a higher percentage of ALF in adults." | 2.44 | Drug-related hepatotoxicity and acute liver failure. ( Bassett, M; Hadzic, N; Kelly, D; Murray, KF; Wirth, S, 2008) |
| "Despite the lack of clinical data on the safety and efficacy of analgesics for the treatment of colds and flu symptoms a case can be made that these medicines are safe and effective for treatment of these common illnesses." | 2.43 | Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. ( Eccles, R, 2006) |
| "Pharmacotherapy in pregnancy is often problematic, since both the mother-to-be and her doctor are often concerned about possible risks for the unborn child." | 2.42 | [Drug therapy in pregnancy--a practical guide]. ( Kreienberg, R; Paulus, W; Reister, F, 2004) |
| "Experience with dose response and mechanisms of toxicity has shown that multiple mechanisms may exist for a single agent along the continuum of the full dose-response curve." | 2.42 | Dose-dependent transitions in mechanisms of toxicity: case studies. ( Andersen, ME; Bogdanffy, MS; Bus, JS; Cohen, SD; Conolly, RB; David, RM; Doerrer, NG; Dorman, DC; Gaylor, DW; Hattis, D; Rogers, JM; Setzer, RW; Slikker, W; Swenberg, JA; Wallace, K, 2004) |
| " Clinical trial evidence supporting shorter NAC dosing now allows the possibility for intensifying treatment without the risk of very high rates of ADRs." | 1.91 | Large paracetamol overdose-Higher dose acetylcysteine is required. ( Bateman, DN, 2023) |
| " Adult evidence demonstrates that alternative dosing regimens decrease NAARs and medication errors (MEs)." | 1.91 | Comparison of Two-Bag Versus Three-Bag N-Acetylcysteine Regimens for Pediatric Acetaminophen Toxicity. ( Camarena-Michel, A; Hoyte, C; Leonard, J; Pennington, S; Sudanagunta, S; Wang, GS, 2023) |
| "The results showed that by strengthening cell protection mechanisms against oxidative stress, geranium extract reduces the toxic effects of acetaminophen on mice's kidney function and thus ameliorates the damage." | 1.72 | Protective Effect of the Hydroalcoholic Extract of Pelargonium Graveolens L. on Rats with Acetaminophen- Induced Nephrotoxicity. ( Akbarpour, B; Asmarian, S; Gholyaf, M; Mohammadi, F, 2022) |
| "Once a baseline incidence is known, predictors for serious ORADEs in surgical inpatients are useful in guiding medical-surgical nurses' opioid safety practices, with more frequent focused respiratory assessments before opioid dosing and closer monitoring when opioids are prescribed postoperatively, especially in higher-risk surgical inpatients." | 1.72 | Incidence of and predictors for serious opioid-related adverse drug events. ( Atem, FD; Denke, L; Khazzam, M, 2022) |
| "She developed encephalopathy and an international normalised ratio of 6." | 1.72 | Intravenous acetaminophen associated with acute liver failure. ( Balinski, A; Bower, R; Lee, M; McCarron, J, 2022) |
| " For PK assessments, we dosed the APAP in the media at preset timepoints after administering it either over the intestinal barrier (emulating the oral route) or in the media (emulating the intravenous route), at 12 µM and 2 µM respectively." | 1.56 | An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment. ( Bortot, LO; de Carvalho, M; Dias, MM; Indolfo, NC; Lorencini, M; Marin, TM; Pagani, E; Rocco, SA; Schuck, DC; Vasconcelos Bento, GI, 2020) |
| "When taken in the recommended dosage, acetaminophen is a safe and effective analgesic and antipyretic agent." | 1.51 | Acute acetaminophen toxicity in adults. ( Saccomano, SJ, 2019) |
| " Thus, the aim of this study was to analyze the toxic effects of pharmaceuticals in non-standard endpoints on two macrophyte species, Lemna minor and Lemna gibba." | 1.51 | Evaluation of pharmaceutical toxic effects of non-standard endpoints on the macrophyte species Lemna minor and Lemna gibba. ( Alkimin, GD; Barata, C; Daniel, D; Frankenbach, S; Nunes, B; Serôdio, J; Soares, AMVM, 2019) |
| "We hypothesized (1) that gastrointestinal (GI) and renal adverse events (AE) would occur more often in infants first prescribed ibuprofen before rather than after six months of age and (2) that ibuprofen would be associated with more adverse effects than acetaminophen in infants younger than six months." | 1.48 | Safety of ibuprofen in infants younger than six months: A retrospective cohort study. ( Bang, H; Rothenberg, SJ; Walsh, P, 2018) |
| " In the present study, we aimed to evaluate the adverse event profiles of OTC combination cold remedy based on the components using the Japanese Adverse Drug Event Report (JADER) database." | 1.48 | [Adverse Event Trends Associated with Over-the-counter Combination Cold Remedy: Data Mining of the Japanese Adverse Drug Event Report Database]. ( Fukuda, A; Hasegawa, S; Hatahira, H; Hirade, K; Iguchi, K; Motooka, Y; Naganuma, M; Nakamura, M; Nakao, S; Sasaoka, S; Shimauchi, A; Ueda, N; Umetsu, R, 2018) |
| "Many patients treated with imatinib, used in cancer treatment, are using several other drugs that could interact with imatinib." | 1.43 | Drug-drug interactions with imatinib: An observational study. ( Bondon-Guitton, E; Bourrel, R; Chebane, L; Despas, F; Lapeyre-Mestre, M; Montastruc, JL; Récoché, I; Rousseau, V, 2016) |
| " In this research, we have explored the feasibility of retrospectively mapping population-level adverse events from the FDA Adverse Event Reporting System (FAERS) to chemical and biological databases to identify drug safety signals and the underlying molecular mechanisms." | 1.43 | Improving drug safety with a systems pharmacology approach. ( Bojunga, N; Lesko, LJ; Schotland, P; Trame, MN; Zien, A, 2016) |
| "About 5,101,841 influenza-like illness cases were reported to the CDC, and 2,122,940 calls regarding reported exposures to medications commonly used to treat ILI, were reported by poison centers to the NPDS over the 13 flu seasons." | 1.43 | Relating calls to US poison centers for potential exposures to medications to Centers for Disease Control and Prevention reporting of influenza-like illness. ( Beauchamp, GA; McKeown, NJ; Rodriguez, S; Spyker, DA, 2016) |
| "Therefore, hepatoma cell lines are widely used as alternatives, although their phases I and II drug-metabolizing activities are substantially lower compared with hHeps." | 1.38 | Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism. ( Dooley, S; Ehnert, S; Hao, L; Lin, J; Liu, L; Mühl-Benninghaus, R; Neumann, J; Nussler, AK; Nussler, N; Schyschka, L; Stöckle, U, 2012) |
| " Microfluidic bioartificial organs enable the spatial and temporal control of cell growth and biochemistry, critical for organ-specific metabolic functions and particularly relevant to testing the metabolic dose-response signatures associated with both pharmaceutical and environmental toxicity." | 1.38 | Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs. ( Baudoin, R; Blaise, BJ; Brochot, C; Defernez, M; Domange, C; Dumas, ME; Leclerc, E; Legallais, C; Navratil, V; Péry, AR; Pontoizeau, C; Prot, JM; Shintu, L; Toulhoat, P, 2012) |
| "Propylhexedrine is a potent α-adrenergic sympathomimetic amine found in nasal decongestant inhalers." | 1.37 | A drug toxicity death involving propylhexedrine and mitragynine. ( Holler, JM; Levine, B; Magluilo, J; McDonough-Bender, PC; Solomon, CJ; Vorce, SP, 2011) |
| " These observations prompted us to investigate whether PGE2 plays a role in host defence to toxic effect of APAP." | 1.36 | The role of prostaglandin E2 in acute acetaminophen hepatotoxicity in mice. ( Cavar, I; Culo, F; Kelava, T; Saraga-Babić, M; Vukojević, K, 2010) |
| " Although both classes of drug are generally well tolerated, they can lead to well-characterized adverse effects." | 1.36 | Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes. ( de Vries, F; Setakis, E; van Staa, TP, 2010) |
| " Therefore, toxic responses to the reactive metabolites have been expected to be expressed more strongly in a glutathione-depleted condition." | 1.36 | In vitro cytotoxicity assay to evaluate the toxicity of an electrophilic reactive metabolite using glutathione-depleted rat primary cultured hepatocytes. ( Fujimoto, K; Kishino, H; Manabe, S; Sanbuissho, A; Yamoto, T, 2010) |
| " Questions were designed to assess physician knowledge of acetaminophen dosing and toxicity, recognition of prescription and over-the-counter products containing acetaminophen, and education provided to patients when prescribing acetaminophen-containing products." | 1.36 | Survey of physician knowledge and counseling practices regarding acetaminophen. ( Andrus, M; Hornsby, LB; Przybylowicz, J; Starr, J, 2010) |
| " Adoption of these two recommendations may lead to the increased use of NSAIDs with the potential of increasing incidence of NSAIDs-related adverse reactions." | 1.36 | FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable? ( Day, RO; Graham, GG; Graudins, A; Mohamudally, A, 2010) |
| "Acute poisoning is a significant health problem all over the world." | 1.33 | MS 04-044: demographic features of drug and chemical poisoning in northern Malaysia. ( Ab Rahman, AF; Fathelrahman, AI; Mohd Zain, Z, 2005) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| "To understand the bioavailability and mechanistic pathways of cytoprotection by IH636 grape seed proanthocyanidin extract (GSPE, commercially known as ActiVin) a series of in vitro and in vivo studies were conducted." | 1.31 | Mechanistic pathways of antioxidant cytoprotection by a novel IH636 grape seed proanthocyanidin extract. ( Bagchi, D; Bagchi, M; Preuss, HG; Ray, SD; Stohs, SJ, 2002) |
| "We have developed an in vitro drug toxicity assay designed to test the hypothesis that differences in susceptibility may be based on genetic abnormalities in the detoxification of electrophilic drug metabolites." | 1.27 | In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. ( Spielberg, SP, 1984) |
| "Several xenobiotics undergo biotransformation reactions which yield reactive and potentially toxic compounds." | 1.27 | The role of metabolic activation in drug toxicity. ( Moldéus, P; Ormstad, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (14.66) | 18.7374 |
| 1990's | 8 (4.19) | 18.2507 |
| 2000's | 40 (20.94) | 29.6817 |
| 2010's | 71 (37.17) | 24.3611 |
| 2020's | 44 (23.04) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Dawson, S | 1 |
| Stahl, S | 1 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 2 |
| Tong, W | 2 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Pelliccia, V | 1 |
| Rossi, S | 1 |
| Zollino, I | 1 |
| Quagliarella, F | 1 |
| Buonocore, G | 1 |
| Saifuddin, A | 1 |
| Koesnoe, S | 1 |
| Kurniati, N | 1 |
| Sirait, S | 1 |
| Arisanty, R | 1 |
| Yunihastuti, E | 1 |
| Kokawa, T | 1 |
| Yamamoto, H | 1 |
| Itoh, M | 1 |
| Shimane, A | 1 |
| Kawai, H | 1 |
| Takaya, T | 1 |
| Thanacoody, HKR | 1 |
| Bateman, DN | 1 |
| Berland, NG | 1 |
| Leonard, J | 2 |
| Calello, DP | 1 |
| Baum, RA | 1 |
| Su, MK | 3 |
| Weant, KA | 1 |
| Yang, Y | 1 |
| Ju, C | 2 |
| Sivilotti, MLA | 3 |
| Yarema, MC | 1 |
| Juurlink, DN | 1 |
| Gholyaf, M | 2 |
| Asmarian, S | 1 |
| Akbarpour, B | 1 |
| Mohammadi, F | 1 |
| Boussetta-Charfi, O | 1 |
| D'Andon, CF | 1 |
| Nguyen, H | 1 |
| Rumack, BH | 2 |
| Launay, M | 1 |
| Sudanagunta, S | 1 |
| Camarena-Michel, A | 1 |
| Pennington, S | 1 |
| Hoyte, C | 1 |
| Wang, GS | 1 |
| Abbasnezhad, A | 1 |
| Salami, F | 1 |
| Mohebbati, R | 1 |
| Niu, H | 1 |
| Atallah, E | 1 |
| Alvarez-Alvarez, I | 1 |
| Medina-Caliz, I | 1 |
| Aithal, GP | 1 |
| Arikan, C | 1 |
| Andrade, RJ | 1 |
| Lucena, MI | 1 |
| Denke, L | 1 |
| Atem, FD | 1 |
| Khazzam, M | 1 |
| Motohashi, K | 1 |
| Thanacoody, RH | 1 |
| Humphries, C | 1 |
| Smith, J | 1 |
| Roberts, G | 1 |
| Kidd, R | 1 |
| Kader, HA | 1 |
| Taheem, A | 1 |
| Chiew, AL | 1 |
| Buckley, NA | 1 |
| Lee, M | 3 |
| McCarron, J | 3 |
| Balinski, A | 3 |
| Bower, R | 3 |
| Yau, CE | 3 |
| Chen, H | 3 |
| Lim, BP | 3 |
| Ng, M | 3 |
| Ponampalam, R | 3 |
| Lim, DYZ | 3 |
| Chin, YH | 3 |
| Ho, AFW | 3 |
| Filip, AB | 2 |
| Mullins, ME | 3 |
| Jaeschke, H | 3 |
| Ramachandran, A | 3 |
| Sun, X | 2 |
| Cui, Q | 2 |
| Ni, J | 2 |
| Liu, X | 2 |
| Zhu, J | 2 |
| Zhou, T | 2 |
| Huang, H | 2 |
| OuYang, K | 2 |
| Wu, Y | 2 |
| Yang, Z | 2 |
| Rajaraman, N | 1 |
| Gray, L | 1 |
| Anderson, M | 1 |
| Kelgeri, C | 1 |
| Burghle, A | 1 |
| Pottegård, A | 1 |
| Rasmussen, M | 1 |
| Bruun, B | 1 |
| Roost Hosbjerg, J | 1 |
| Lundby, C | 1 |
| Spyker, DA | 2 |
| Marano, M | 1 |
| Roversi, M | 1 |
| Severini, F | 1 |
| Memoli, C | 1 |
| Musolino, A | 1 |
| Pisani, M | 1 |
| Cecchetti, C | 1 |
| Villani, A | 1 |
| Strehle, EM | 1 |
| Haar, I | 1 |
| Ghany, MG | 1 |
| Watkins, PB | 3 |
| Albert, K | 1 |
| Wilson, K | 2 |
| Hasara, S | 1 |
| Lyngstad, G | 1 |
| Skjelbred, P | 1 |
| Swanson, DM | 1 |
| Skoglund, LA | 1 |
| Dart, RC | 3 |
| Matoushek, T | 1 |
| Ruha, AM | 1 |
| Burns, MM | 1 |
| Simone, K | 1 |
| Beuhler, MC | 1 |
| Heard, KJ | 1 |
| Mazer-Amirshahi, M | 1 |
| Stork, CM | 1 |
| Varney, SM | 1 |
| Funk, AR | 1 |
| Cantrell, LF | 1 |
| Cole, JB | 1 |
| Banner, W | 1 |
| Stolbach, AI | 1 |
| Hendrickson, RG | 1 |
| Lucyk, SN | 1 |
| Nelson, LS | 1 |
| Abushanab, D | 1 |
| Gasim, M | 1 |
| Devi, D | 1 |
| Elbdairy, M | 1 |
| Elqasass, H | 1 |
| Ahmed, N | 1 |
| Vincent, M | 1 |
| Abdul Rouf, PV | 1 |
| Mohammed, HR | 1 |
| Hail, MA | 1 |
| Thomas, B | 1 |
| Elkassem, W | 1 |
| Hanssens, Y | 1 |
| Elgassim, M | 1 |
| Elmoheen, A | 1 |
| Azad, A | 1 |
| Mohammed, S | 1 |
| Salem, W | 1 |
| Graudins, A | 6 |
| Wong, A | 5 |
| Saccomano, SJ | 1 |
| Sandoval, J | 1 |
| Orlicky, DJ | 1 |
| Allawzi, A | 1 |
| Butler, B | 1 |
| Phan, CT | 1 |
| Toston, R | 1 |
| De Dios, R | 1 |
| Nguyen, L | 1 |
| McKenna, S | 1 |
| Nozik-Grayck, E | 1 |
| Wright, CJ | 1 |
| Chau-Glendinning, H | 1 |
| Baber, B | 1 |
| Neher, JO | 1 |
| Weinstein, RB | 1 |
| Ryan, PB | 1 |
| Berlin, JA | 1 |
| Schuemie, MJ | 1 |
| Swerdel, J | 1 |
| Fife, D | 1 |
| Maskell, KF | 1 |
| Powell, SW | 1 |
| Willis, D | 1 |
| Okhomina, V | 1 |
| Sima, AP | 1 |
| Wills, BK | 1 |
| Hayden, JC | 1 |
| Kelly, L | 1 |
| McNicholas, F | 1 |
| Hall, B | 1 |
| Blind, F | 1 |
| Marin, TM | 1 |
| Indolfo, NC | 1 |
| Rocco, SA | 1 |
| de Carvalho, M | 1 |
| Dias, MM | 1 |
| Vasconcelos Bento, GI | 1 |
| Bortot, LO | 1 |
| Schuck, DC | 1 |
| Lorencini, M | 1 |
| Pagani, E | 1 |
| McDougall, G | 1 |
| Murphy, NG | 1 |
| Loubani, O | 1 |
| Hedenmalm, K | 1 |
| Pacurariu, A | 1 |
| Slattery, J | 1 |
| Kurz, X | 1 |
| Candore, G | 1 |
| Flynn, R | 1 |
| O'Callaghan, C | 1 |
| Zolot, J | 1 |
| Gunja, N | 1 |
| McNulty, R | 1 |
| Rakowsky, S | 1 |
| Spiller, HA | 1 |
| Casavant, MJ | 1 |
| Chounthirath, T | 1 |
| Hodges, NL | 1 |
| Kim, EH | 1 |
| Smith, GA | 1 |
| Harmouche, E | 2 |
| Howland, MA | 2 |
| K Su, M | 1 |
| Krpo, M | 1 |
| Arnestad, M | 1 |
| Karinen, R | 1 |
| Sasaoka, S | 1 |
| Hatahira, H | 1 |
| Hasegawa, S | 1 |
| Motooka, Y | 1 |
| Fukuda, A | 1 |
| Naganuma, M | 1 |
| Umetsu, R | 1 |
| Nakao, S | 1 |
| Shimauchi, A | 1 |
| Ueda, N | 1 |
| Hirade, K | 1 |
| Iguchi, K | 1 |
| Nakamura, M | 1 |
| Kumar, RD | 1 |
| Premnath, U | 1 |
| Reynard, C | 1 |
| Howard, L | 1 |
| Hoffman, RS | 1 |
| Joo, Y | 1 |
| Cruickshanks, KJ | 1 |
| Klein, BEK | 1 |
| Klein, R | 1 |
| Hong, O | 1 |
| Wallhagen, M | 1 |
| Walsh, P | 1 |
| Rothenberg, SJ | 1 |
| Bang, H | 1 |
| Gu, X | 1 |
| Albrecht, W | 1 |
| Edlund, K | 1 |
| Kappenberg, F | 1 |
| Rahnenführer, J | 1 |
| Leist, M | 1 |
| Moritz, W | 1 |
| Godoy, P | 1 |
| Cadenas, C | 1 |
| Marchan, R | 1 |
| Brecklinghaus, T | 1 |
| Pardo, LT | 1 |
| Castell, JV | 1 |
| Gardner, I | 1 |
| Han, B | 1 |
| Hengstler, JG | 1 |
| Stoeber, R | 1 |
| Alkimin, GD | 1 |
| Daniel, D | 1 |
| Frankenbach, S | 1 |
| Serôdio, J | 1 |
| Soares, AMVM | 1 |
| Barata, C | 1 |
| Nunes, B | 1 |
| Arnall, JR | 1 |
| Moore, DC | 1 |
| Hill, HL | 1 |
| Griffin, S | 1 |
| Mueller, MK | 1 |
| Lavery, LA | 1 |
| Voorhees, PM | 1 |
| Usmani, SZ | 1 |
| Porto, HKP | 1 |
| Grando, MD | 1 |
| Ramalho, LNZ | 1 |
| Valadares, MC | 1 |
| Bendhack, LM | 1 |
| Batista, AC | 1 |
| Rocha, ML | 1 |
| Riste, M | 1 |
| Trafford, G | 1 |
| Osimani, B | 2 |
| Rashid, K | 1 |
| Sinha, K | 1 |
| Sil, PC | 1 |
| Chalhoub, WM | 1 |
| Sliman, KD | 1 |
| Arumuganathan, M | 1 |
| Lewis, JH | 2 |
| Prymula, R | 1 |
| Esposito, S | 1 |
| Zuccotti, GV | 1 |
| Xie, F | 1 |
| Toneatto, D | 1 |
| Kohl, I | 1 |
| Dull, PM | 1 |
| Mignini, F | 1 |
| Urban, M | 1 |
| Cagáňová, B | 1 |
| Plačková, S | 1 |
| Kurcová, I | 1 |
| Pelclova, D | 1 |
| Darnis, D | 1 |
| Mahé, J | 1 |
| Vrignaud, B | 1 |
| Guen, CG | 1 |
| Veyrac, G | 1 |
| Jolliet, P | 1 |
| Thompson, RA | 1 |
| Isin, EM | 1 |
| Ogese, MO | 1 |
| Mettetal, JT | 1 |
| Williams, DP | 3 |
| Beauchamp, GA | 1 |
| McKeown, NJ | 1 |
| Rodriguez, S | 1 |
| Vatakuti, S | 1 |
| Pennings, JL | 1 |
| Gore, E | 1 |
| Olinga, P | 1 |
| Groothuis, GM | 1 |
| Clarke, JI | 1 |
| Dear, JW | 1 |
| Antoine, DJ | 2 |
| Schotland, P | 1 |
| Bojunga, N | 1 |
| Zien, A | 1 |
| Trame, MN | 1 |
| Lesko, LJ | 1 |
| Bartoli, F | 1 |
| Bruni, C | 1 |
| Cometi, L | 1 |
| Blagojevic, J | 1 |
| Fiori, G | 1 |
| Tofani, L | 1 |
| Galluccio, F | 1 |
| Furst, DE | 1 |
| Matucci Cerinic, M | 1 |
| Récoché, I | 1 |
| Rousseau, V | 1 |
| Bourrel, R | 1 |
| Lapeyre-Mestre, M | 1 |
| Chebane, L | 1 |
| Despas, F | 1 |
| Montastruc, JL | 1 |
| Bondon-Guitton, E | 1 |
| Ciejka, M | 1 |
| Nguyen, K | 1 |
| Bluth, MH | 1 |
| Dubey, E | 1 |
| Mosedale, M | 1 |
| Sirois, JE | 1 |
| Murray, KF | 1 |
| Hadzic, N | 1 |
| Wirth, S | 1 |
| Bassett, M | 1 |
| Kelly, D | 1 |
| Oliveras-Moreno, JM | 1 |
| Hernandez-Pacheco, E | 1 |
| Oliveras-Quintana, T | 1 |
| Infante-Cossio, P | 1 |
| Gutierrez-Perez, JL | 1 |
| Park, BK | 3 |
| Spooner, N | 1 |
| Lad, R | 1 |
| Barfield, M | 1 |
| Chun, LJ | 1 |
| Tong, MJ | 1 |
| Busuttil, RW | 1 |
| Hiatt, JR | 1 |
| Wang, K | 1 |
| Zhang, S | 1 |
| Marzolf, B | 1 |
| Troisch, P | 1 |
| Brightman, A | 1 |
| Hu, Z | 1 |
| Hood, LE | 1 |
| Galas, DJ | 1 |
| Oshikoya, KA | 1 |
| Alzoubi, KH | 1 |
| Mhaidat, N | 1 |
| Azzam, SA | 1 |
| Khader, Y | 1 |
| Salem, S | 1 |
| Issaifan, H | 1 |
| Haddadin, R | 1 |
| Athuraliya, TN | 1 |
| Jones, AL | 1 |
| Gupta, AK | 1 |
| Chan, GM | 1 |
| Greller, HA | 1 |
| Bertuola, F | 1 |
| Morando, C | 1 |
| Menniti-Ippolito, F | 1 |
| Da Cas, R | 1 |
| Capuano, A | 1 |
| Perilongo, G | 1 |
| Da Dalt, L | 1 |
| Koliou, M | 1 |
| Ioannou, C | 1 |
| Andreou, K | 1 |
| Petridou, A | 1 |
| Soteriades, ES | 1 |
| Han, D | 1 |
| Shinohara, M | 1 |
| Ybanez, MD | 1 |
| Saberi, B | 1 |
| Kaplowitz, N | 2 |
| Haag, G | 1 |
| Graham, GG | 1 |
| Day, RO | 1 |
| Mohamudally, A | 1 |
| PASCUCCI, F | 1 |
| NOFERI, G | 1 |
| Cavar, I | 1 |
| Kelava, T | 1 |
| Vukojević, K | 1 |
| Saraga-Babić, M | 1 |
| Culo, F | 1 |
| Liss, G | 1 |
| Rattan, S | 1 |
| O'Connell, TM | 1 |
| Huang, J | 1 |
| Shi, W | 1 |
| Zhang, J | 1 |
| Chou, JW | 1 |
| Paules, RS | 1 |
| Gerrish, K | 1 |
| Li, J | 1 |
| Luo, J | 1 |
| Wolfinger, RD | 1 |
| Bao, W | 1 |
| Chu, TM | 1 |
| Nikolsky, Y | 1 |
| Nikolskaya, T | 1 |
| Dosymbekov, D | 1 |
| Tsyganova, MO | 1 |
| Shi, L | 1 |
| Fan, X | 1 |
| Corton, JC | 1 |
| Chen, M | 1 |
| Cheng, Y | 1 |
| Bushel, PR | 1 |
| de Vries, F | 1 |
| Setakis, E | 1 |
| van Staa, TP | 1 |
| Fujimoto, K | 1 |
| Kishino, H | 1 |
| Yamoto, T | 1 |
| Manabe, S | 1 |
| Sanbuissho, A | 1 |
| Stirnimann, G | 1 |
| Kessebohm, K | 1 |
| Lauterburg, B | 1 |
| Baillie, TA | 1 |
| Rettie, AE | 1 |
| Lavonas, EJ | 1 |
| Reynolds, KM | 1 |
| Van Summeren, A | 1 |
| Renes, J | 1 |
| Bouwman, FG | 1 |
| Noben, JP | 1 |
| van Delft, JH | 1 |
| Kleinjans, JC | 1 |
| Mariman, EC | 1 |
| Holler, JM | 1 |
| Vorce, SP | 1 |
| McDonough-Bender, PC | 1 |
| Magluilo, J | 1 |
| Solomon, CJ | 1 |
| Levine, B | 1 |
| Hornsby, LB | 1 |
| Przybylowicz, J | 1 |
| Andrus, M | 1 |
| Starr, J | 1 |
| Lin, J | 1 |
| Schyschka, L | 1 |
| Mühl-Benninghaus, R | 1 |
| Neumann, J | 1 |
| Hao, L | 1 |
| Nussler, N | 1 |
| Dooley, S | 1 |
| Liu, L | 1 |
| Stöckle, U | 1 |
| Nussler, AK | 1 |
| Ehnert, S | 1 |
| Maesschalck, PJ | 1 |
| Yorgason, JG | 1 |
| Luxford, W | 1 |
| Kalinec, F | 1 |
| Pach, D | 1 |
| Brinkhaus, B | 1 |
| Roll, S | 1 |
| Wegscheider, K | 1 |
| Icke, K | 1 |
| Willich, SN | 1 |
| Witt, CM | 1 |
| Shintu, L | 1 |
| Baudoin, R | 1 |
| Navratil, V | 1 |
| Prot, JM | 1 |
| Pontoizeau, C | 1 |
| Defernez, M | 1 |
| Blaise, BJ | 1 |
| Domange, C | 1 |
| Péry, AR | 1 |
| Toulhoat, P | 1 |
| Legallais, C | 1 |
| Brochot, C | 1 |
| Leclerc, E | 1 |
| Dumas, ME | 1 |
| Jefferies, S | 1 |
| Saxena, M | 1 |
| Young, P | 1 |
| Clark, R | 1 |
| Fisher, JE | 1 |
| Sketris, IS | 1 |
| Johnston, GM | 1 |
| Lai, DP | 1 |
| Ren, XH | 1 |
| Yao, JP | 1 |
| Liu, ML | 1 |
| Xu, G | 1 |
| Chen, ZJ | 1 |
| Ling, GL | 1 |
| Aronowitz, RA | 1 |
| Claesson, A | 1 |
| Spjuth, O | 1 |
| Cao, L | 1 |
| Waldon, D | 1 |
| Teffera, Y | 1 |
| Roberts, J | 1 |
| Wells, M | 1 |
| Langley, M | 1 |
| Zhao, Z | 1 |
| Schmidt, LE | 1 |
| Dalhoff, K | 1 |
| Carvajal García-Pando, A | 1 |
| Bagchi, D | 1 |
| Ray, SD | 1 |
| Bagchi, M | 1 |
| Preuss, HG | 1 |
| Stohs, SJ | 1 |
| Mokhlesi, B | 1 |
| Leikin, JB | 1 |
| Murray, P | 1 |
| Corbridge, TC | 1 |
| Anton, C | 1 |
| Ferner, RE | 1 |
| Zhuo, X | 1 |
| Gu, J | 1 |
| Behr, MJ | 1 |
| Swiatek, PJ | 1 |
| Cui, H | 1 |
| Zhang, QY | 1 |
| Xie, Y | 1 |
| Collins, DN | 1 |
| Ding, X | 1 |
| Reister, F | 1 |
| Paulus, W | 1 |
| Kreienberg, R | 1 |
| Bischoff, A | 1 |
| Slikker, W | 1 |
| Andersen, ME | 1 |
| Bogdanffy, MS | 1 |
| Bus, JS | 1 |
| Cohen, SD | 1 |
| Conolly, RB | 1 |
| David, RM | 1 |
| Doerrer, NG | 1 |
| Dorman, DC | 1 |
| Gaylor, DW | 1 |
| Hattis, D | 1 |
| Rogers, JM | 1 |
| Setzer, RW | 1 |
| Swenberg, JA | 1 |
| Wallace, K | 1 |
| Gonzalez, FJ | 1 |
| Fathelrahman, AI | 1 |
| Ab Rahman, AF | 1 |
| Mohd Zain, Z | 1 |
| McCuskey, RS | 1 |
| Salhanick, SD | 1 |
| Belikoff, B | 1 |
| Orlow, D | 1 |
| Holt, D | 1 |
| Reenstra, W | 1 |
| Buras, JA | 1 |
| Ikeda, T | 1 |
| Eccles, R | 1 |
| Park, KB | 1 |
| Dalton-Brown, E | 1 |
| Hirst, C | 1 |
| Mendoza, CD | 1 |
| Heard, K | 1 |
| Khashab, M | 1 |
| Tector, AJ | 1 |
| Kwo, PY | 1 |
| Gunawan, BK | 1 |
| Chodorowski, Z | 1 |
| Sein Anand, J | 1 |
| Rybakowska, I | 1 |
| Kaletha, K | 1 |
| Ottewell, L | 1 |
| Walker, DJ | 1 |
| Lee, WM | 2 |
| Squires, RH | 1 |
| Fontana, RJ | 1 |
| Prescott, LF | 1 |
| Spielberg, SP | 1 |
| Stewart, MJ | 1 |
| Levy, G | 1 |
| Galinsky, RE | 1 |
| Lin, JH | 1 |
| Gillette, JR | 1 |
| Finch, N | 1 |
| Salaspuro, M | 1 |
| Lesca, P | 1 |
| Mitchell, JR | 3 |
| Corcoran, GB | 1 |
| Smith, CV | 1 |
| Hughes, H | 1 |
| Lauterburg, BH | 3 |
| Jollow, DJ | 1 |
| Roberts, S | 1 |
| Price, V | 1 |
| Smith, C | 1 |
| Steineck, G | 1 |
| Wiholm, BE | 1 |
| Gerhardsson de Verdier, M | 1 |
| Jørgensen, G | 1 |
| Hanzlick, R | 1 |
| Kraft, KE | 1 |
| Dore, FH | 1 |
| Pirmohamed, M | 1 |
| Kitteringham, NR | 1 |
| Ostapowicz, G | 1 |
| Cunningham, MJ | 1 |
| Liang, S | 1 |
| Fuhrman, S | 1 |
| Seilhamer, JJ | 1 |
| Somogyi, R | 1 |
| Chu, J | 1 |
| Wang, RY | 1 |
| Hill, NS | 1 |
| Pessayre, D | 1 |
| Benhamou, JP | 1 |
| Levine, L | 1 |
| Sherlock, S | 1 |
| Nelson, SD | 1 |
| Thorgeirsson, SS | 1 |
| McMurtry, RJ | 1 |
| Dybing, E | 2 |
| Baumgarten, R | 1 |
| Mathew, TH | 1 |
| Ryan, EH | 1 |
| Jampol, LM | 1 |
| Guengerich, FP | 1 |
| Liebler, DC | 1 |
| Hayes, MA | 1 |
| Pickering, DB | 1 |
| Hennigar, GR | 1 |
| Ormstad, K | 1 |
| Moldéus, P | 1 |
| May, FE | 1 |
| Stewart, RB | 1 |
| Cluff, LE | 1 |
| Moses, AM | 1 |
| Miller, M | 1 |
| Boyd, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients[NCT01491919] | Phase 1 | 26 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Evaluation of MicroRNA Expression in Blood and Cytology Specimens as a Novel Method for Detecting Barrett's Esophagus[NCT02464930] | 220 participants (Anticipated) | Observational | 2015-04-30 | Recruiting | |||
| A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers[NCT01541800] | 20 participants (Anticipated) | Observational | 2010-03-31 | Recruiting | |||
| Prospective Randomized Controlled Multicentre Trial for Patients With Chronic Low Back Pain Comparing Disci/Rhus Toxicodendron Comp.®, Placebo and Waiting List Group[NCT00567736] | Phase 3 | 150 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Potassium values will be obtained at Baseline and Day 14 prior to the final dose of study drug. Mean calculated from the two measurements. (NCT01491919)
Timeframe: At baseline visit and Day 14 prior to final study dose.
| Intervention | mEq/L (Mean) |
|---|---|
| Low Dose: Lisinopril | 0.1 |
| Medium Dose: Lisinopril | -0.3 |
| High Dose: Lisinopril | 0.3 |
Change in urine protein/creatinine obtained as follows: Mean change (worst post-dose from baseline) presented for urine protein/creatinine ratio. Geometric mean of the ratio (worst post-dose / baseline with Geometric Coefficient of Variation percent (CV%) and greatest decrease presented for eGFR by dose group. Two patients in the high dose group had an evaluable urine protein/creatinine change. (NCT01491919)
Timeframe: Baseline to worst post-dose before Day 14 (+/- 3 days)
| Intervention | mg/mg (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | -0.45 |
| Medium Dose: Lisinopril | -0.08 |
| High Dose: Lisinopril | -0.74 |
"The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitor (ACEI) mediated reduction in kidney function.~Largest eGFR percent decrease from baseline reported in results section." (NCT01491919)
Timeframe: Baseline to Day 14 (+/- 3 days)
| Intervention | percentage (Number) |
|---|---|
| Low Dose: Lisinopril | 15 |
| Medium Dose: Lisinopril | 12 |
| High Dose: Lisinopril | 21 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of AUC. Geometric mean was calculated from all measurements. (NCT01491919)
Timeframe: Day 14 (+/- 3 days) of lisinopril therapy at hours 0 (pre-dose) and 1,2,4,5,8,12 and 24 hrs after dose
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 298 |
| Medium Dose: Lisinopril | 640 |
| High Dose: Lisinopril | 702 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of Cmax. Geometric mean was calculated from all measurements. (NCT01491919)
Timeframe: Day14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Intervention | ng/ml (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 20.9 |
| Medium Dose: Lisinopril | 47.7 |
| High Dose: Lisinopril | 58.0 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CL/F. Geometric mean was calculated from all measurements. (NCT01491919)
Timeframe: Day 14 (+/- 3 d) of dose at 0 hour and at 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Intervention | L/h/70 kg (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 17.9 |
| Medium Dose: Lisinopril | 18.6 |
| High Dose: Lisinopril | 32.8 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of plasma lisinopril concentration. Medium was calculated from all measurements. (NCT01491919)
Timeframe: Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Intervention | hours (Median) |
|---|---|
| Low Dose: Lisinopril | 5.0 |
| Medium Dose: Lisinopril | 5.0 |
| High Dose: Lisinopril | 4.5 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CLrenal. Geometric mean was calculated from all measurements. (NCT01491919)
Timeframe: Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose.
| Intervention | L/h/70 kg (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 3.4 |
| Medium Dose: Lisinopril | 3.4 |
| High Dose: Lisinopril | 6.8 |
The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitors (ACE-I)-mediated reduction in kidney function. eGFR ratio was computed from the worst post-dose value divided by the Baseline value. (NCT01491919)
Timeframe: Baseline to Day 14 (+/- 3 days)
| Intervention | ratio (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 1 |
| Medium Dose: Lisinopril | 1.02 |
| High Dose: Lisinopril | 0.89 |
Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements (note: the participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40. The mean from the blood pressure measurements was calculated. (NCT01491919)
Timeframe: Screening to Day 14 to 40
| Intervention | mmHg (Mean) | |
|---|---|---|
| eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0) | eGFR >=60 ml/min per 1.73m2 (n=5, 2, 0) | |
| Low Dose: Lisinopril | -6.0 | 3.4 |
| Medium Dose: Lisinopril | -6.5 | -3.0 |
"Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.~Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).~The mean of these measurements was calculated." (NCT01491919)
Timeframe: Baseline to Day 14 (+/-3 days)
| Intervention | mmHg (Mean) | |
|---|---|---|
| eGFR 30-59 ml/min per 1.73m^2 (n=3, 1, 0) | eGFR >=60 ml/min per 1.73m^2 (n=3, 5, 3) | |
| High Dose: Lisinopril | NA | -4.0 |
| Low Dose: Lisinopril | -4.0 | -9.0 |
| Medium Dose: Lisinopril | 7.0 | -6.0 |
Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements. Note: these participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40 (inclusive). The mean of these blood pressure measurements was calculated. (NCT01491919)
Timeframe: Screening to Day 14 to 40
| Intervention | mmHg (Mean) | |
|---|---|---|
| eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0) | eGFR >=60 ml/min per 1.73m2 (n=5, 2, 0) | |
| Low Dose: Lisinopril | -6.0 | 6.4 |
| Medium Dose: Lisinopril | -1.0 | -1.0 |
"Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.~Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).~The mean from these measurements was calculated." (NCT01491919)
Timeframe: Baseline to Day 14 (+/- 3 days)
| Intervention | mmHg (Mean) | |
|---|---|---|
| eGFR 30-59 ml/min per 1.73m2 (n=3, 1, 0) | eGFR >+60 ml/min per 1.732 (n=3, 5, 3) | |
| High Dose: Lisinopril | NA | -11.3 |
| Low Dose: Lisinopril | -5.0 | -6.7 |
| Medium Dose: Lisinopril | -6.0 | -8.8 |
Number of Adverse Events (AEs) related and not related to study drug; number of Serious Adverse Events (SAEs) related and not related to study drug (NCT01491919)
Timeframe: First dose of study drug to 30 days after final study visit for AEs and until resolution for SAEs
| Intervention | events (Number) | ||||
|---|---|---|---|---|---|
| AEs | AE related to study drug | AEs not related to study drug | SAE | SAE not related to study drug | |
| Lisinopril Standard of Care (SOC) | 12 | 0 | 12 | 0 | 0 |
| Lisinopril-naive | 12 | 5 | 7 | 1 | 1 |
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
| Intervention | Percent Change (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 41.2 |
| Maximum Dose Level 6.65 g/24h | 16.6 |
| Maximum Dose Level 10 g/24h | 41.8 |
| Maximum Dose Level 20g/24h | 38.4 |
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
| Intervention | micrograms per millileter (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 65.6 |
| Maximum Dose Level 6.65 g/24h | 32.2 |
| Maximum Dose Level 10 g/24h | 33.4 |
| Maximum Dose Level 20g/24h | 104.9 |
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 23.8 |
| Maximum Dose Level 6.65 g/24h | 24.0 |
| Maximum Dose Level 10 g/24h | 24.0 |
| Maximum Dose Level 20g/24h | 24.0 |
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 2.4 |
| Maximum Dose Level 6.65 g/24h | 3.2 |
| Maximum Dose Level 10 g/24h | 1.6 |
| Maximum Dose Level 20g/24h | 1.8 |
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 0 |
| Maximum Dose Level 6.65 g/24h | 0 |
| Maximum Dose Level 10 g/24h | 0 |
| Maximum Dose Level 20g/24h | 0 |
56 reviews available for acetaminophen and Adverse Drug Event
| Article | Year |
|---|---|
A review: Systematic research approach on toxicity model of liver and kidney in laboratory animals.
Topics: Acetaminophen; Animals; Animals, Laboratory; Chemical and Drug Induced Liver Injury; Drug-Related Si | 2022 |
Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adrenal Cortex Hormones; Adult; Carnitine; Chemical and D | 2022 |
Toxicology in the emergency department: what's new?
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Australia; Drug Overdose; Drug-R | 2022 |
Performance of the paracetamol-aminotransferase multiplication product in risk stratification after paracetamol (acetaminophen) poisoning: a systematic review and meta-analysis.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injur | 2023 |
Performance of the paracetamol-aminotransferase multiplication product in risk stratification after paracetamol (acetaminophen) poisoning: a systematic review and meta-analysis.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injur | 2023 |
Performance of the paracetamol-aminotransferase multiplication product in risk stratification after paracetamol (acetaminophen) poisoning: a systematic review and meta-analysis.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injur | 2023 |
Performance of the paracetamol-aminotransferase multiplication product in risk stratification after paracetamol (acetaminophen) poisoning: a systematic review and meta-analysis.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injur | 2023 |
Do prophylactic antipyretics reduce vaccination-associated symptoms in children?
Topics: Acetaminophen; Antipyretics; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reaction | 2020 |
A clinician's guide to self-poisoning with paracetamol in youth: The what, when and why?
Topics: Acetaminophen; Acetylcysteine; Adolescent; Analgesics, Non-Narcotic; Child; Drug Overdose; Drug-Rela | 2020 |
Novel Regimens in the Treatment of Paracetamol (Acetaminophen) Poisoning.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug-Related Side Effects and Adverse Reactions; Humans; Pa | 2017 |
An update on oxidative stress-mediated organ pathophysiology.
Topics: Acetaminophen; Animals; Antioxidants; Arsenic; Cadmium; Carbon Tetrachloride; Cisplatin; Diabetes Me | 2013 |
Drug-induced liver injury: what was new in 2013?
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Dr | 2014 |
Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Chemical | 2016 |
Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon?
Topics: Acetaminophen; Biomarkers; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adv | 2016 |
Drug Toxicities of Common Analgesic Medications in the Emergency Department.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Chemical and Drug Induced Liver Injury; Dose-Respo | 2017 |
Drug-related hepatotoxicity and acute liver failure.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Child; Drug-Related Side Effects and Adverse Reactio | 2008 |
Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anesthetics, Inhalation; Animals; Biotransformation; Chemic | 2008 |
Acetaminophen hepatotoxicity and acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Adult; Drug Overdose; Drug-Related Side Effects and Adverse Reactions | 2009 |
Signal transduction pathways involved in drug-induced liver injury.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Biotransformation; Chemical and Drug Induced Liver | 2010 |
[Self-medication of primary headaches].
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Diclof | 2009 |
Predicting and preventing acute drug-induced liver injury: what's new in 2010?
Topics: Acetaminophen; Adult; Aged; Aging; Alanine Transaminase; Amoxicillin-Potassium Clavulanate Combinati | 2010 |
The application of metabonomics to predict drug-induced liver injury.
Topics: Acetaminophen; Animals; Azetidines; Benzylamines; Chemical and Drug Induced Liver Injury; Clinical T | 2010 |
Liver injury caused by drugs: an update.
Topics: Acetaminophen; Adaptive Immunity; Analgesics, Non-Narcotic; Antitubercular Agents; Apoptosis; Chemic | 2010 |
Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.
Topics: Acetaminophen; Animals; Biotransformation; Chemical and Drug Induced Liver Injury; Cytochrome P-450 | 2011 |
Therapeutic acetaminophen is not associated with liver injury in children: a systematic review.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Child; Dose-Response Relationship, Dr | 2010 |
[Efficacy and safety of ibuprofen and paracetamol in fever among children].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Drug Combin | 2011 |
In vitro and in vivo models of drug ototoxicity: studying the mechanisms of a clinical problem.
Topics: Acetaminophen; Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 2011 |
Paracetamol in critical illness: a review.
Topics: Acetaminophen; Analgesics; Antipyretics; Critical Illness; Drug-Related Side Effects and Adverse Rea | 2012 |
On mechanisms of reactive metabolite formation from drugs.
Topics: Acetaminophen; Carboxylic Acids; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Sys | 2013 |
Adult toxicology in critical care: Part II: specific poisonings.
Topics: Acetaminophen; Alcohols; Cyanides; Drug-Related Side Effects and Adverse Reactions; Emergencies; Hum | 2003 |
[Drug therapy in pregnancy--a practical guide].
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Bacte | 2004 |
Dose-dependent transitions in mechanisms of toxicity: case studies.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Androgen Antagonists; Animals; Butadienes; Dichloroethylene | 2004 |
Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1.
Topics: Acetaminophen; Animals; Apoptosis; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2E1; | 2005 |
Sinusoidal endothelial cells as an early target for hepatic toxicants.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Advers | 2006 |
[Drug-induced liver injury].
Topics: Acetaminophen; Anesthetics, General; Animals; Benzoquinones; Chemical and Drug Induced Liver Injury; | 2006 |
Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Com | 2006 |
Selection of new chemical entities with decreased potential for adverse drug reactions.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Drug Design; Drug-R | 2006 |
Epidemiology of acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Drug-Related Side Effects and Adverse React | 2007 |
Mechanisms of drug-induced liver disease.
Topics: Acetaminophen; Apoptosis; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adve | 2007 |
[Heme oxygenase as a potential therapeutic target for hepatoprotection].
Topics: Acetaminophen; Animals; Biliverdine; Carbon Monoxide; Catalysis; Cells, Cultured; Chemical and Drug | 2007 |
Etiologies of acute liver failure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Budd-Chiari Syndrome; Drug-Related Side Effects and Adverse | 2008 |
Acute liver failure in children.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Child; Drug-Related Side Effects a | 2008 |
Acute liver failure due to drugs.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug Overdose; Drug-Related Side Effects and Adverse Reacti | 2008 |
Reactive metabolites as a cause of hepatotoxicity.
Topics: Acetaminophen; Animals; Biotransformation; Chemical and Drug Induced Liver Injury; Drug-Related Side | 1983 |
Drug analyses in poisoned patients--the need to be specific.
Topics: Acetaminophen; Barbiturates; Chlormethiazole; Clinical Laboratory Techniques; Colorimetry; Diagnosti | 1982 |
Pharmacokinetic consequences and toxicologic implications of endogenous cosubstrate depletion.
Topics: Acetaminophen; Animals; Drug-Related Side Effects and Adverse Reactions; Kinetics; Pharmaceutical Pr | 1982 |
The problem of chemically reactive metabolites.
Topics: Acetaminophen; Animals; Biotransformation; Chemical Phenomena; Chemistry; Chloroform; Drug-Related S | 1982 |
Toxicological considerations for the medicinal chemist.
Topics: Acetaminophen; Amines; Animals; Anticonvulsants; Biotransformation; Chemistry, Pharmaceutical; Drug- | 1981 |
Metabolic activation and toxicology - some models of chemical protection against drug toxicity.
Topics: Acetaminophen; Animals; Biotransformation; Chemical and Drug Induced Liver Injury; Chloroform; Cytoc | 1981 |
The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity.
Topics: Abnormalities, Drug-Induced; Acetaminophen; Chemical and Drug Induced Liver Injury; Cytochrome P-450 | 1995 |
Acute hepatic failure: a Western perspective.
Topics: Acetaminophen; Acetylcysteine; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; He | 2000 |
Update in clinical toxicology.
Topics: Acetaminophen; Antivenins; Calcium Channel Blockers; Drug-Related Side Effects and Adverse Reactions | 2002 |
Reported ocular side effects of the ten most frequently prescribed drugs.
Topics: Acetaminophen; Ampicillin; Brompheniramine; Codeine; Diazepam; Digoxin; Drug Prescriptions; Drug-Rel | 1979 |
Metabolic activation: biochemical basis for many drug-induced liver injuries.
Topics: Acetaminophen; Animals; Binding Sites; Carcinogens; Chemical and Drug Induced Liver Injury; Drug Hyp | 1976 |
Drug-induced renal disease.
Topics: Acetaminophen; Acute Kidney Injury; Analgesics; Angiotensin-Converting Enzyme Inhibitors; Anti-Infla | 1992 |
Enzymatic activation of chemicals to toxic metabolites.
Topics: Acetaminophen; Alkylation; Animals; Biotransformation; Chemical Phenomena; Chemistry; Cytochrome P-4 | 1985 |
[Drug damage to the liver: role of reactive metabolites and pharmacokinetics].
Topics: Acetaminophen; Amiodarone; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adv | 1985 |
Drug-induced dilutional hyponatremia.
Topics: Acetaminophen; Amitriptyline; Animals; Anura; Body Fluids; Carbamazepine; Chlorpropamide; Clofibrate | 1974 |
4 trials available for acetaminophen and Adverse Drug Event
| Article | Year |
|---|---|
Analgesic effect of oral paracetamol 1000 mg/ibuprofen 400 mg, paracetamol 1000 mg/codeine 60 mg, paracetamol 1000 mg/ibuprofen 400 mg/codeine 60 mg, or placebo on acute postoperative pain: a single-dose, randomized, and double-blind study.
Topics: Acetaminophen; Adult; Analgesics; Analgesics, Non-Narcotic; Codeine; Double-Blind Method; Drug-Relat | 2023 |
A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).
Topics: Acetaminophen; Antipyretics; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infant | 2014 |
Efficacy and safety of sodium hyaluronate in the treatment of Wilkes stage II disease.
Topics: Acetaminophen; Administration, Oral; Adult; Aged; Arthralgia; Drug Combinations; Drug-Related Side E | 2008 |
Efficacy of injections with Disci/Rhus toxicodendron compositum for chronic low back pain--a randomized placebo-controlled trial.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Chron | 2011 |
131 other studies available for acetaminophen and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Adverse Drug Reactions of Acetaminophen and Ibuprofen in the Paediatric Population: Analysis of the Italian Spontaneous Reporting Database.
Topics: Acetaminophen; Adolescent; Adverse Drug Reaction Reporting Systems; Child; Child, Preschool; Drug-Re | 2022 |
COVID Arm After Moderna Booster in Healthcare Worker: A Case Report.
Topics: 2019-nCoV Vaccine mRNA-1273; Acetaminophen; Analgesics, Non-Narcotic; Biopsy; COVID-19; COVID-19 Vac | 2021 |
Fever-Related Ventricular Fibrillation - Potential Adverse Effect of SARS-CoV-2 Vaccination in Patients With Brugada Syndrome.
Topics: Acetaminophen; Adult; Anti-Arrhythmia Agents; Antipyretics; Arrhythmias, Cardiac; Brugada Syndrome; | 2022 |
Large paracetamol overdose - Higher dose NAC is NOT required.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Dru | 2023 |
Large paracetamol overdose-Higher dose acetylcysteine is required.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Chemical and Drug Induced Liver | 2023 |
Should the Dosage Cap Be Used in Patients Greater than 100 kg Receiving N-acetylcysteine for Acetaminophen Toxicity?
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Drug-Related Side Effects and Adverse React | 2022 |
The Cents of the Dosage Cap in Patients Greater than 100 Kilograms Receiving N-Acetylcysteine for Acetaminophen Toxicity.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Drug-Related Side Effects and Adverse React | 2022 |
Sulfation in Acetaminophen-Induced Liver Injury: Friend or Foe?
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury, Chronic; Drug-Related Side Effects and Advers | 2022 |
Treating acetaminophen overdose.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Drug Overdose; Drug | 2022 |
What dose of paracetamol for people with low bodyweight?
Topics: Acetaminophen; Adult; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Humans | 2022 |
Protective Effect of the Hydroalcoholic Extract of Pelargonium Graveolens L. on Rats with Acetaminophen- Induced Nephrotoxicity.
Topics: Acetaminophen; Animals; Creatinine; Drug-Related Side Effects and Adverse Reactions; Mice; Pelargoni | 2022 |
Failure of Risk Assessment After Paracetamol Overdose-A Short Communication.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Drug Overdos | 2023 |
Comparison of Two-Bag Versus Three-Bag N-Acetylcysteine Regimens for Pediatric Acetaminophen Toxicity.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adult; Analgesics, Non-Narcotic; Antidotes; Child; Cohort | 2023 |
Incidence of and predictors for serious opioid-related adverse drug events.
Topics: Acetaminophen; Analgesics, Opioid; Drug-Related Side Effects and Adverse Reactions; Humans; Hydrocod | 2022 |
SNAPTIMED study: does the Scottish and Newcastle Anti-emetic Protocol achieve timely intervention and management from the emergency department to discharge for paracetamol poisoning?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antiemetics; Drug Overdose; Drug-Related Side Effects and A | 2022 |
Comment on: "population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations".
Topics: Acetaminophen; Analgesics, Non-Narcotic; Delayed-Action Preparations; Drug Compounding; Drug Overdos | 2023 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Intravenous acetaminophen associated with acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Brain Diseases; Drug-Related Side Effects and Adverse Reactions; Fema | 2022 |
Fomepizole should be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Drug Overdose; Drug-Related Side | 2023 |
Fomepizole should be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Drug Overdose; Drug-Related Side | 2023 |
Fomepizole should be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Drug Overdose; Drug-Related Side | 2023 |
Fomepizole should be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Drug Overdose; Drug-Related Side | 2023 |
Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice.
Topics: Acetaminophen; Animals; Antibodies; Chemical and Drug Induced Liver Injury; Drug-Related Side Effect | 2023 |
Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice.
Topics: Acetaminophen; Animals; Antibodies; Chemical and Drug Induced Liver Injury; Drug-Related Side Effect | 2023 |
Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice.
Topics: Acetaminophen; Animals; Antibodies; Chemical and Drug Induced Liver Injury; Drug-Related Side Effect | 2023 |
Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice.
Topics: Acetaminophen; Animals; Antibodies; Chemical and Drug Induced Liver Injury; Drug-Related Side Effect | 2023 |
Reply to Jaeschke and Ramachandran, "Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice".
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Advers | 2023 |
Reply to Jaeschke and Ramachandran, "Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice".
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Advers | 2023 |
Reply to Jaeschke and Ramachandran, "Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice".
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Advers | 2023 |
Reply to Jaeschke and Ramachandran, "Putative Effects of an Orally Administered Anti-TLR4 Antibody on Gut Microbiota and Acetaminophen Hepatotoxicity in Mice".
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Advers | 2023 |
Paracetamol overdose in children: management following an initial N-acetylcysteine regimen.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Child; Drug Overdose; Drug-Relat | 2023 |
Use of analgesics in Denmark: A national survey.
Topics: Acetaminophen; Adolescent; Adult; Analgesics; Denmark; Drug-Related Side Effects and Adverse Reactio | 2023 |
The authors' reply to comment on "Population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations".
Topics: Acetaminophen; Analgesics, Non-Narcotic; Delayed-Action Preparations; Drug Compounding; Drug Overdos | 2023 |
Adverse drugs reactions to paracetamol and ibuprofen in children: a 5-year report from a pediatric poison control center in Italy.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Child; Child, Preschool; Drug-Related Side Effects and Adve | 2023 |
Acute kidney injury after treatment of paracetamol overdose using new N-acetylcysteine guideline.
Topics: Acetaminophen; Acetylcysteine; Acute Kidney Injury; Analgesics, Non-Narcotic; Drug Overdose; Drug-Re | 2023 |
Moving the Needle to Reduce Acetaminophen (Paracetamol) Hepatotoxicity.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Drug-Related Side E | 2023 |
Implementation of a pharmacist toxicology service on treatment of paracetamol (acetaminophen) overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Dru | 2023 |
Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement.
Topics: Acetaminophen; Acetylcysteine; Ambulatory Care; Canada; Child; Drug-Related Side Effects and Adverse | 2023 |
Patterns and outcomes of paracetamol poisoning management in Hamad Medical Corporation, Qatar: A retrospective cohort study.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adult; Drug Overdose; Drug-Related Side Effects and Adver | 2023 |
Paracetamol overdose: limiting the potential for harm.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Australia; Drug Overdose; Drug-Related Side Effects and Adv | 2019 |
Acute acetaminophen toxicity in adults.
Topics: Acetaminophen; Adult; Drug-Related Side Effects and Adverse Reactions; Humans; Nurse Practitioners; | 2019 |
Toxic Acetaminophen Exposure Induces Distal Lung ER Stress, Proinflammatory Signaling, and Emphysematous Changes in the Adult Murine Lung.
Topics: Acetaminophen; Animals; Cells, Cultured; Cytochrome P-450 CYP2E1; Disease Models, Animal; Drug-Relat | 2019 |
Letter to the Editor Regarding the Article "Chrysin Effect in Prevention of Acetaminophen-Induced Hepatotoxicity in Rat" by Mohammadi and Co-Workers (2019).
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Advers | 2020 |
Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen.
Topics: Acetaminophen; Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Ag | 2020 |
Patterns of transaminase elevation in rhabdomyolysis versus acetaminophen toxicity.
Topics: Acetaminophen; Adult; Chemical and Drug Induced Liver Injury; Clinical Enzyme Tests; Diagnosis, Diff | 2021 |
Clinical Progress Note: Goal-Directed N-acetylcysteine Treatment of Acetaminophen Toxicity.
Topics: Acetaminophen; Acetylcysteine; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Goals | 2021 |
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment.
Topics: Acetaminophen; Animals; Caco-2 Cells; Cell Nucleus; Drug-Related Side Effects and Adverse Reactions; | 2020 |
N-Acetylcysteine treatment of neonatal acetaminophen toxicity caused by transplacental transfer - a case report.
Topics: Acetaminophen; Acetylcysteine; Adult; Analgesics, Non-Narcotic; Brain Diseases; Chemical and Drug In | 2021 |
Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Coho | 2021 |
A two-bag acetylcysteine regimen is associated with shorter delays and interruptions in the treatment of paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Australia; Drug Overdose; Drug-R | 2022 |
Long-Term NSAIDs and Acetaminophen Linked to Hearing Loss in Women.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Drug-Related Side Effects and Adverse Reacti | 2017 |
Accuracy of the paracetamol-aminotransferase product to predict hepatotoxicity in paracetamol overdose treated with a 2-bag acetylcysteine regimen.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adult; Analgesics, Non-Narcotic; Antidotes; Drug Overdose | 2018 |
Antipyretic Medication Exposures Among Young Children Reported to US Poison Centers, 2000-2015.
Topics: Acetaminophen; Age Distribution; Antipyretics; Child; Child, Preschool; Confidence Intervals; Databa | 2018 |
In response to: "Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning".
Topics: Acetaminophen; Acetylcysteine; Alanine Transaminase; Analgesics, Non-Narcotic; Antidotes; Drug Overd | 2018 |
Determination of Acetaminophen, Dexchlorpheniramine, Caffeine, Cotinine and Salicylic acid in 100 μL of Whole Blood by UHPLC-MS/MS.
Topics: Acetaminophen; Autopsy; Caffeine; Child, Preschool; Chlorpheniramine; Chromatography, High Pressure | 2018 |
[Adverse Event Trends Associated with Over-the-counter Combination Cold Remedy: Data Mining of the Japanese Adverse Drug Event Report Database].
Topics: Acetaminophen; Adverse Drug Reaction Reporting Systems; Biliary Tract Diseases; Chemical and Drug In | 2018 |
Bet 1: A slower rate of initial N-acetylcysteine infusion in the treatment of acute paracetamol overdose to reduce adverse reactions.
Topics: Acetaminophen; Acetylcysteine; Administration, Intravenous; Antidotes; Drug Overdose; Drug-Related S | 2018 |
In response to: fewer adverse effects with a modified two-bag acetylcysteine protocol in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Human | 2018 |
Prevalence of ototoxic medication use among older adults in Beaver Dam, Wisconsin.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2018 |
Safety of ibuprofen in infants younger than six months: A retrospective cohort study.
Topics: Acetaminophen; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ibuprofen; Incidence | 2018 |
Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes.
Topics: Acetaminophen; Cell Culture Techniques; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cry | 2018 |
Evaluation of pharmaceutical toxic effects of non-standard endpoints on the macrophyte species Lemna minor and Lemna gibba.
Topics: Acetaminophen; Anthocyanins; Aquatic Organisms; Araceae; Carotenoids; Catalase; Chlorophyll A; Chlor | 2019 |
Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
Topics: Acetaminophen; Ambulatory Care; Antibodies, Monoclonal; Antineoplastic Agents; Cancer Care Facilitie | 2019 |
Exposure to acetaminophen impairs vasodilation, increases oxidative stress and changes arterial morphology of rats.
Topics: Acetaminophen; Animals; Antioxidants; Aorta, Thoracic; Drug-Related Side Effects and Adverse Reactio | 2019 |
Adverse reactions.
Topics: Acetaminophen; Drug-Related Side Effects and Adverse Reactions; Floxacillin; Humans | 2019 |
Until RCT proven? On the asymmetry of evidence requirements for risk assessment.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Asthma; Data Interpretation, Statistical; Drug-Related Side | 2013 |
Causal assessment of pharmaceutical treatments: why standards of evidence should not be the same for benefits and harms?
Topics: Acetaminophen; Asthma; Bayes Theorem; Causality; Drug-Related Side Effects and Adverse Reactions; Hu | 2015 |
Paracetamol poisonings in the Czech and Slovak Republic and N-acetylcysteine treatment. Data analysis.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Child; Child, P | 2014 |
Adverse Drug Reactions in Pediatric Emergency Medicine.
Topics: Acetaminophen; Adolescent; Adverse Drug Reaction Reporting Systems; Amoxicillin; Child; Child, Presc | 2015 |
Simplification of the standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions.
Topics: Acetaminophen; Acetylcysteine; Administration, Intravenous; Adolescent; Adult; Anaphylaxis; Drug Ove | 2016 |
Relating calls to US poison centers for potential exposures to medications to Centers for Disease Control and Prevention reporting of influenza-like illness.
Topics: Acetaminophen; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Analge | 2016 |
Classification of Cholestatic and Necrotic Hepatotoxicants Using Transcriptomics on Human Precision-Cut Liver Slices.
Topics: Acetaminophen; Aged; Benzofurans; Bile Acids and Salts; Chloramphenicol; Chlorpromazine; Cholestasis | 2016 |
N-acetylcysteine regimens for paracetamol overdose: Time for a change?
Topics: Acetaminophen; Acetylcysteine; Administration, Intravenous; Analgesics, Non-Narcotic; Antidotes; Dru | 2016 |
Improving drug safety with a systems pharmacology approach.
Topics: Acetaminophen; Adverse Drug Reaction Reporting Systems; Analgesics, Non-Narcotic; Anticonvulsants; C | 2016 |
Premedication prevents infusion reactions and improves retention rate during infliximab treatment.
Topics: Acetaminophen; Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Chlor | 2016 |
Drug-drug interactions with imatinib: An observational study.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antineoplastic | 2016 |
Consumer Healthcare Products Association response to Major et al., "Trends in rates of acetaminophen-related adverse events in the United States", Pharmacoepidemiology & Drug Safety, May 2016, 25: 590-8.
Topics: Acetaminophen; Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reacti | 2017 |
Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method.
Topics: Acetaminophen; Blood Chemical Analysis; Blood Circulation; Blood Specimen Collection; Clinical Trial | 2009 |
Circulating microRNAs, potential biomarkers for drug-induced liver injury.
Topics: Acetaminophen; Animals; Biomarkers; Chemical and Drug Induced Liver Injury; Drug Overdose; Drug-Rela | 2009 |
Circulating microRNAs, potential biomarkers for drug-induced liver injury.
Topics: Acetaminophen; Animals; Biomarkers; Chemical and Drug Induced Liver Injury; Drug Overdose; Drug-Rela | 2009 |
Circulating microRNAs, potential biomarkers for drug-induced liver injury.
Topics: Acetaminophen; Animals; Biomarkers; Chemical and Drug Induced Liver Injury; Drug Overdose; Drug-Rela | 2009 |
Circulating microRNAs, potential biomarkers for drug-induced liver injury.
Topics: Acetaminophen; Animals; Biomarkers; Chemical and Drug Induced Liver Injury; Drug Overdose; Drug-Rela | 2009 |
Paracetamol induced angioedema: More details required.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Angioedema; Child, Preschool; Drug-Related Side Effects and | 2008 |
Prevalence of migraine and tension-type headache among adults in Jordan.
Topics: Acetaminophen; Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Analgesics; Drug-Relate | 2009 |
Prolonged N-acetylcysteine therapy in late acetaminophen poisoning associated with acute liver failure--a need to be more cautious?
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Animals; Antidotes; Drug Administration Sch | 2009 |
NAC: still the way to go.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Animals; Antidotes; Drug-Related Side Effec | 2009 |
Is acetaminophen safe? Accidental overdoses are common, but avoidable.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Drug Labeling; Drug | 2010 |
Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy.
Topics: Acetaminophen; Acute Disease; Adolescent; Adverse Drug Reaction Reporting Systems; Anti-Bacterial Ag | 2010 |
The epidemiology of childhood poisonings in Cyprus.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Cyprus; Drug-Related S | 2010 |
FDA proposals to limit the hepatotoxicity of paracetamol (acetaminophen): are they reasonable?
Topics: Acetaminophen; Advisory Committees; Alcohol Drinking; Analgesics, Opioid; Anti-Inflammatory Agents, | 2010 |
Antirheumatic therapy and devitaminizing action of drugs; effects of rubrophen on the ascorbic acid content of various parenchymes and protective action of vitamin C against the onset of tissue lesions caused by the drug.
Topics: Acetaminophen; Ascorbic Acid; Aurintricarboxylic Acid; Drug-Related Side Effects and Adverse Reactio | 1945 |
The role of prostaglandin E2 in acute acetaminophen hepatotoxicity in mice.
Topics: Acetaminophen; Alanine Transaminase; Animals; Cytoprotection; Dinoprostone; Drug Overdose; Drug-Rela | 2010 |
Genomic indicators in the blood predict drug-induced liver injury.
Topics: Acetaminophen; Algorithms; Analgesics, Non-Narcotic; Artificial Intelligence; Biomarkers; Carbon Tet | 2010 |
Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
In vitro cytotoxicity assay to evaluate the toxicity of an electrophilic reactive metabolite using glutathione-depleted rat primary cultured hepatocytes.
Topics: Acetaminophen; Animals; Buthionine Sulfoximine; Cells, Cultured; Drug Approval; Drug-Related Side Ef | 2010 |
Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells.
Topics: Acetaminophen; Amiodarone; Blotting, Western; Cell Survival; Chemical and Drug Induced Liver Injury; | 2011 |
A drug toxicity death involving propylhexedrine and mitragynine.
Topics: Acetaminophen; Chromatography, Liquid; Drug-Related Side Effects and Adverse Reactions; Evaluation S | 2011 |
Survey of physician knowledge and counseling practices regarding acetaminophen.
Topics: Acetaminophen; Alabama; Analgesics, Non-Narcotic; Clinical Competence; Directive Counseling; Drug In | 2010 |
FDA limits prescription acetaminophen. But be vigilant about over-the-counter acetaminophen, too.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Dose-Response Relat | 2011 |
Comparative analysis of phase I and II enzyme activities in 5 hepatic cell lines identifies Huh-7 and HCC-T cells with the highest potential to study drug metabolism.
Topics: Acetaminophen; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Cytochrome P-450 Enzyme | 2012 |
Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs.
Topics: Acetaminophen; Ammonia; Analgesics, Non-Narcotic; Animals; Bioartificial Organs; Cells, Cultured; Ch | 2012 |
Population prevalence of high dose paracetamol in dispensed paracetamol/opioid prescription combinations: an observational study.
Topics: Acetaminophen; Aged; Analgesics, Opioid; Drug Prescriptions; Drug-Related Side Effects and Adverse R | 2012 |
[Study on the effect using hemoperfusion to treat tylenol poisoned patients].
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Overdose; Drug-Related Side Effe | 2012 |
The social and economic influences on medication use and misuse.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Drug-Related Side E | 2012 |
Ratios of biliary glutathione disulfide (GSSG) to glutathione (GSH): a potential index to screen drug-induced hepatic oxidative stress in rats and mice.
Topics: Acetaminophen; Animals; Bile; Diquat; Drug Evaluation, Preclinical; Drug-Related Side Effects and Ad | 2013 |
The effect of regular medication on the outcome of paracetamol poisoning.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opi | 2002 |
[Other risks from drugs: the case of acetaminophen].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Drug Overdose; Drug-Related Side Effects and Adverse Reacti | 2002 |
Mechanistic pathways of antioxidant cytoprotection by a novel IH636 grape seed proanthocyanidin extract.
Topics: Acetaminophen; Administration, Oral; Alanine Transaminase; Amiodarone; Analgesics, Non-Narcotic; Ani | 2002 |
Medication errors detected in infusions.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Antidotes; Drug-Related Side Effects and Ad | 2003 |
Targeted disruption of the olfactory mucosa-specific Cyp2g1 gene: impact on acetaminophen toxicity in the lateral nasal gland, and tissue-selective effects on Cyp2a5 expression.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cyto | 2004 |
[Increased quality of life--your patient does not tolerate his medication?].
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug-Relate | 2004 |
MS 04-044: demographic features of drug and chemical poisoning in northern Malaysia.
Topics: Accidents; Acetaminophen; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Dem | 2005 |
Hyperbaric oxygen reduces acetaminophen toxicity and increases HIF-1alpha expression.
Topics: Acetaminophen; Alanine Transaminase; Animals; Biomarkers; Disease Models, Animal; Drug-Related Side | 2006 |
Coma, metabolic acidosis and normal liver function in a child with a large serum acetaminophen level.
Topics: Acetaminophen; Acidosis; Child, Preschool; Coma; Drug-Related Side Effects and Adverse Reactions; Fe | 2006 |
Overdose risk prompts UK withdrawal of propoxyphene combination.
Topics: Acetaminophen; Dextropropoxyphene; Drug Combinations; Drug Overdose; Drug-Related Side Effects and A | 2006 |
Co-proxamol: where have all the patients gone?
Topics: Acetaminophen; Aged; Analgesics; Arthritis, Rheumatoid; Dextropropoxyphene; Dose-Response Relationsh | 2008 |
In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans.
Topics: Acetaminophen; Biotransformation; Drug-Related Side Effects and Adverse Reactions; Glutathione Synth | 1984 |
[Drug-induced liver damage; new aspects on its mechanism].
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Chlorpromazine; Contraceptives, Oral; Drug-Re | 1980 |
Alkylation and peroxidation injury from chemically reactive metabolites.
Topics: Acetaminophen; Acetylcysteine; Alkylation; Animals; Antioxidants; Biotransformation; Drug-Related Si | 1981 |
Biochemical basis for dose response relationships in reactive metabolite toxicity.
Topics: Acetaminophen; Animals; Biotransformation; Cricetinae; Diabetes Mellitus, Experimental; Drug-Related | 1981 |
Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study.
Topics: Acetaminophen; Age Factors; Analgesics; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Aspir | 1995 |
[Effects of drugs on the liver. A review illustrated with 3 clinical cases].
Topics: Acetaminophen; Adult; Aged; Androgens; Chemical and Drug Induced Liver Injury; Denmark; Disulfiram; | 1994 |
[Drug-induced digestive system diseases. Discussion].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Digestive System Diseases; Drug-Related Side | 1995 |
National Association of Medical Examiners Pediatric Toxicology (PedTox) Registry Report 3. Case submission summary and data for acetaminophen, benzene, carboxyhemoglobin, dextromethorphan, ethanol, phenobarbital, and pseudoephedrine.
Topics: Acetaminophen; Benzene; Carboxyhemoglobin; Child, Preschool; Coroners and Medical Examiners; Dextrom | 1995 |
Computerized drug interaction programs: how reliable?
Topics: Acetaminophen; Adult; Antidepressive Agents; Antipyrine; Chloral Hydrate; Drug Combinations; Drug In | 1996 |
Gene expression microarray data analysis for toxicology profiling.
Topics: Acetaminophen; Animals; Benzo(a)pyrene; Clofibrate; Drug-Related Side Effects and Adverse Reactions; | 2000 |
[Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug | 1979 |
Hepatic reactions to drugs.
Topics: Acetaminophen; Adenoma; Adult; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injur | 1979 |
Drug-induced liver injury.
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Drug-Related | 1978 |
[Drug induced liver injury. Chemical liver necrosis caused by formation of reactive metabolites].
Topics: Acetaminophen; Animals; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug | 1976 |
[Adverse drug effects and the liver].
Topics: Acetaminophen; Adult; Aged; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Ad | 1992 |
Metabolic basis of adverse drug reactions.
Topics: Acetaminophen; Acetylation; Adrenergic beta-Antagonists; Adult; Age Factors; Child; Debrisoquin; Dru | 1986 |
Drug-induced acute transient myopia with retinal folds.
Topics: Acetaminophen; Adult; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Myopia; Retin | 1986 |
Comparative cytopathology of primary rat hepatocyte cultures exposed to aflatoxin B1, acetaminophen, and other hepatotoxins.
Topics: Acetaminophen; Aflatoxin B1; Aflatoxins; Animals; Cells, Cultured; Dimethyl Sulfoxide; Drug-Related | 1985 |
Iatrogenic drug toxicity.
Topics: Acetaminophen; Age Factors; Amphotericin B; Chemical and Drug Induced Liver Injury; Drug Interaction | 1985 |
The role of metabolic activation in drug toxicity.
Topics: Acetaminophen; Animals; Biotransformation; Chemical Phenomena; Chemistry; Cytochrome P-450 Enzyme Sy | 1985 |
Drug use in the hospital: evaluation of determinants.
Topics: Acetaminophen; Aluminum Hydroxide; Analgesics; Antacids; Anti-Bacterial Agents; Chloral Hydrate; Dex | 1974 |
Editorial: The pursuit of a chimera.
Topics: Acetaminophen; Animals; Aspirin; Barbiturates; Chloroform; Dogs; Drug-Related Side Effects and Adver | 1974 |
100-day LD 50 index of chronic toxicity.
Topics: Acetaminophen; Administration, Oral; Animals; Aspirin; Atropine; Caffeine; DDT; Drug-Related Side Ef | 1971 |